Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 12:12 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 73 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Receptor Blockade Clear all

Conditions: Pharmacokinetics of ASKP1240, Pharmacodynamics of ASKP1240, Healthy Volunteers
Interventions: ASKP1240; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Retinopathy of Prematurity
Interventions: Bevacizumab (Avastin); Drug
Lead sponsor: Children's Hospital Los Angeles; Other
Eligibility: 30 Weeks and older
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Type 2 Diabetes, Obesity
Interventions: Doxycycline, Placebo; Drug · Other
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 60 Years
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Pain
Interventions: Adding Magnesium Sulfate to the standard epidural and interscalene blocks for chronic pain; Drug
Lead sponsor: State University of New York - Upstate Medical University; Other
Eligibility: 18 Years and older
U.S. locations: 1
States / cities: East Syracuse, New York

Conditions: Gastric Cancer, Precancerous Condition
Interventions: Cetuximab; Biological
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2010
U.S. locations: 3
States / cities: Nashville, Tennessee

Conditions: Diabetes
Interventions: Ramipril, Candesartan cilexetil, Allopurinol; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 21 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Malignant Epithelial Neoplasms
Interventions: TCR-transduced T cells, CDX-1140, Pembrolizumab; Biological · Drug
Lead sponsor: Providence Health & Services; Other
Eligibility: Not listed
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Asthma (Diagnosis), Persistent Asthma, Moderate Asthma Exacerbation
Interventions: Anakinra 100 Mg/0.67 Ml Inj Syringe, Saline Placebo/0.67 Ml Inj Syringe; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Thoracic Aortic Aneurysm
Interventions: Spironolactone, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Cardiorenal Syndrome (CRS)
Interventions: Candesartan, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Psychedelic Effects in Healthy Volunteers
Interventions: Pindolol, Placebo, Psilocybin; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 21 Years to 60 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Type 1 Diabetes
Interventions: Exercise, Spironolactone; Other · Drug
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years to 50 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Breast Neoplasms, Neoplasms, Hormone-Dependent
Interventions: Atamestane, toremifene, letrozole; Drug
Lead sponsor: Intarcia Therapeutics; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 6
States / cities: Greenbrae, California • Saint Joseph, Michigan • Kansas City, Missouri + 3 more

Conditions: Delayed Graft Function
Interventions: OPN-305, Placebo; Drug
Lead sponsor: Opsona Therapeutics Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 252 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 14
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Tampa, Florida + 10 more

Conditions: Receptor Blockade
Interventions: Adenosine Triphosphate, Acetylcholine, Sodium Nitroprusside, Adenosine Diphosphate, Adenosine Monophosphate, Uridine Triphosphate, Adenosine, Vitamin B 6, Pyridoxal 5'-Phosphate; Drug
Lead sponsor: Colorado State University; Other
Eligibility: 18 Years to 30 Years
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Fort Collins, Colorado

Conditions: Pulmonary Hypertension
Interventions: Not listed
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 100 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Sarcoma, HER-2 Protein Overexpression, Osteosarcoma, Rhabdomyosarcoma, Ewing Sarcoma, Synovial Sarcoma, Soft Tissue Sarcoma, Undifferentiated Sarcoma
Interventions: T cells or CAR T cells, Pembrolizumab Injectable Product, Nivolumab Injectable Product; Genetic · Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 1 Year to 25 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2043
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Solid Tumors, Advanced Cancer
Interventions: Anastrozole, Bevacizumab, Everolimus, Sorafenib, Erlotinib; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 277 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2021
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Cardiovascular Diseases, Vascular Dilation
Interventions: Ifetroban Sodium, Placebo; Drug
Lead sponsor: Jeffrey Rade; Other
Eligibility: 18 Years to 80 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Worcester, Massachusetts

Conditions: Primary Immune Thrombocytopenia
Interventions: Ianalumab, Eltrombopag, Placebo; Biological · Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 9
States / cities: Yuma, Arizona • Aurora, Colorado • Evanston, Illinois + 6 more

Conditions: Lung Transplant Recipient
Interventions: Anakinra; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Hyperandrogenism, Polycystic Ovary Syndrome, Puberty
Interventions: Micronized progesterone, Spironolactone, Placebo; Drug
Lead sponsor: University of Virginia; Other
Eligibility: 10 Years to 17 Years · Female only
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2025
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Migraine
Interventions: Erenumab, Placebo, PACAP-38 Challenge Agent; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Anaheim, California

Conditions: Myelodysplastic Syndromes
Interventions: SX-682, Decitabine; Drug
Lead sponsor: Syntrix Biosystems, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 151 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 7
States / cities: Jacksonville, Florida • Miami, Florida • Orlando, Florida + 4 more

Search by objective public record fields.

Bioavailability of ASKP1240 in Healthy Subjects After Intravenous and Subcutaneous Administration of ASKP1240

Use of Pan-vascular Endothelial Growth Factor Receptor (Pan-VEGF) Blockade for the Treatment of Retinopathy of Prematurity (ROP) (Compassionate Use BLOCK-ROP)

Examination of the Anti-inflammatory and Insulin Sensitizing Properties of Doxycycline in Humans

The Effect of Adding Magnesium Sulfate to Standard Epidural and Interscalene Block in Treatment of Patients With Chronic Pain

Cetuximab in Treating Patients With Ménétrier Disease at High Risk of Developing Stomach Cancer

Impact of Diabetes on Left Ventricular Remodeling

Hotspot TCR-T: A Phase I/Ib Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T)

Anakinra Rescue Treatment for Moderate Asthma Attacks (ARTMA)

HEART: Pilot Randomized Controlled Trial

CR Aim #2 - AT1 Receptor Blockade & ACE Inhibition Effect on Humoral Function

Psilocybin Administration With 5-HT1a Blockade

The Impact of Fitness and Mineralocorticoid Receptor Blockade on Vascular Dysfunction in Adults With Type 1 Diabetes

Treatment and Survival Continuation Study of Atamestane Plus Toremifene vs Letrozole in Advanced Breast Cancer

Placebo-Controlled Study to Evaluate the Safety and Efficacy of OPN-305 in Preventing Delayed Renal Graft Function

Pyridoxine, P2 Receptor Antagonism, and ATP-mediated Vasodilation in Young Adults

Effect of Endothelin-1 Receptor Blockade on Circulating Endothelial Microparticles Levels in Patients With Pulmonary Hypertension

HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma

Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance

Thromboxane Receptor Antagonist to Improve Endothelial Function

A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids

BRIDGE - Blocking Receptor of IL-1β for Donor Graft Edema Reduction

Hyperandrogenemia and Altered Day-night LH Pulse Patterns

To Evaluate the Blockade of CGRP in Preventing PACAP-38 Induced Migraine-like Attacks With AMG 334 in Migraine Patients

Study of SX-682 Alone and in Combination With Oral or Intravenous Decitabine in Subjects With Myelodysplastic Syndrome